Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

combination therapy

  • The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens
    Pharmacology
    The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens

    The Mycobacterium tuberculosis drug discovery effort has generated a substantial number of new/repurposed drugs for therapy for this pathogen. The arrival of these drugs is welcome, but another layer of difficulty has emerged.

    G. L. Drusano, Sarah Kim, Mohammed Almoslem, Stephan Schmidt, D. Z. D’Argenio, Jenny Myrick, Brandon Duncanson, Jocelyn Nole, David Brown, C. A. Peloquin, Michael Neely, Walter Yamada, Arnold Louie
  • Pharmacometric Analysis of Tribendimidine Monotherapy and Combination Therapies To Achieve High Cure Rates in Patients with Hookworm Infections
    Clinical Therapeutics
    Pharmacometric Analysis of Tribendimidine Monotherapy and Combination Therapies To Achieve High Cure Rates in Patients with Hookworm Infections

    In the treatment of hookworm infections, pharmacotherapy has been only moderately successful and drug resistance is a threat. Therefore, novel treatment options including combination therapies should be considered, in which tribendimidine could play a role. Our aims were to (i) characterize the pharmacokinetics of tribendimidine’s metabolites in adolescents receiving tribendimidine monotherapy or in combination with ivermectin or...

    Janneke M. Brussee, Anna Neodo, Jessica D. Schulz, Jean T. Coulibaly, Marc Pfister, Jennifer Keiser
  • Activity of Tigecycline or Colistin in Combination with Zidovudine against <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Harboring <em>tet</em>(X) and <em>mcr-1</em>
    Experimental Therapeutics
    Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring tet(X) and mcr-1

    Alternative therapeutic options are urgently needed against multidrug-resistant Escherichia coli infections, especially in situations of preexisting tigecycline and colistin resistance. Here, we investigated synergistic activity of the antiretroviral drug zidovudine in combination with tigecycline or colistin against...

    Yu-Feng Zhou, Ping Liu, Shu-He Dai, Jian Sun, Ya-Hong Liu, Xiao-Ping Liao
  • Evaluation of the Combination of Azithromycin and Naphthoquine in Animal Malaria Models
    Experimental Therapeutics
    Evaluation of the Combination of Azithromycin and Naphthoquine in Animal Malaria Models

    Combination therapy using drugs with different mechanisms of action is the current state of the art in antimalarial treatment. However, except for artemisinin-based combination therapies, only a few other combinations are now available. Increasing concern regarding the emergence and spread of artemisinin resistance in Plasmodium falciparum has led to a need for the...

    Zhu-Chun Bei, Guo-Fu Li, Jing-Hua Zhao, Min Zhang, Xiao-Guang Ji, Jing-Yan Wang
  • Building Optimal Three-Drug Combination Chemotherapy Regimens
    Experimental Therapeutics
    Building Optimal Three-Drug Combination Chemotherapy Regimens

    Multidrug therapy is often required. Examples include antiviral therapy, nosocomial infections, and, most commonly, anti-Mycobacterium tuberculosis therapy. Our laboratory previously identified a mathematical approach to identify 2-drug regimens with a synergistic or additive interaction using a full factorial study design. Our objective here was to generate a method...

    G. L. Drusano, Michael N. Neely, Sarah Kim, Walter M. Yamada, Stephan Schmidt, Brandon Duncanson, Jocelyn Nole, Nino Mtchedlidze, Charles A. Peloquin, Arnold Louie
  • Open Access
    Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Bacteremia: a Systematic Review and Meta-analysis
    Clinical Therapeutics
    Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis

    Infections due to methicillin-resistant Staphylococcus aureus bacteremia (MRSAB) seriously threaten public health due to poor outcomes and high mortality. The objective of this study is to perform a systematic review and meta-analysis of the current evidence on adjuvant β-lactam (BL) therapy combined with vancomycin (VAN) or daptomycin (DAP) for MRSAB. PubMed, Embase...

    Chunjiang Wang, Chao Ye, Linglong Liao, Zhaohui Wang, Ying Hu, Chao Deng, Liang Liu
  • Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus
    Antiviral Agents
    Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus

    Human influenza A and B viruses are highly contagious and cause similar illnesses and seasonal epidemics. Currently available antiviral drugs have limited efficacy in humans with compromised immune systems; therefore, alternative strategies for protection are needed. Here, we investigated whether monoclonal antibodies (MAbs) targeting hemagglutinin (HA) and/or neuraminidase (NA) proteins would protect immunosuppressed mice from severe...

    Bindumadhav M. Marathe, Guha Asthagiri Arunkumar, Peter Vogel, Philippe Noriel Q. Pascua, Jeremy Jones, Richard J. Webby, Florian Krammer, Elena A. Govorkova
  • Amlodipine Increases the Therapeutic Potential of Ravuconazole upon <span class="named-content genus-species" id="named-content-1">Trypanosoma cruzi</span> Infection
    Experimental Therapeutics
    Amlodipine Increases the Therapeutic Potential of Ravuconazole upon Trypanosoma cruzi Infection

    Mining existing agents that enhance the therapeutic potential of ergosterol biosynthesis inhibitors (EBI) is a promising approach to improve Chagas disease chemotherapy. In this study, we evaluated the effect of ravuconazole, an EBI, combined with amlodipine, a calcium channel blocker, upon Trypanosoma cruzi experimental infection. In vitro assays confirmed...

    Yara Almeida Machado, Maria Terezinha Bahia, Ivo Santana Caldas, Ana Lia Mazzeti, Rômulo Dias Novaes, Breno Raimundo Vilas Boas, Lorena Júnia de Souza Santos, Olindo Assis Martins-Filho, Marcos José Marques, Lívia de Figueiredo Diniz
  • Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Bacteremia
    Minireview
    Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia

    Methicillin-resistant Staphylococcus aureus (MRSA) has grown to become a major burden on health care systems. The cumulation of limited therapeutic options and worsened patient outcomes with persistent MRSA bacteremia has driven research in optimizing its initial management. The guidelines published by the Infectious Diseases Society of America currently recommend...

    H Andrew Wilsey, Donna R. Burgess, David S. Burgess
  • The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Bloodstream Infections
    Editor's Pick Minireview
    The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

    Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) are associated with substantial morbidity and mortality. Monotherapy with first-line antimicrobials such as vancomycin (VAN; glycopeptide) and daptomycin (DAP; lipopeptide) are inadequate in some cases due to reduced antibiotic susceptibilities or therapeutic failure. In recent years, β-...

    Kyle C. Molina, Taylor Morrisette, Matthew A. Miller, Vanthida Huang, Douglas N. Fish

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596